A research team led by McGill University has taken a close look at a long-standing idea about Parkinson’s disease and found it needs revision. Working with colleagues at the Douglas Research Centre, ...

A new study from McGill University challenges a decades-old belief about dopamine. Rather than driving movement like a ...

A new study shows dopamine isn’t the brain’s movement “gas pedal” after all. Instead of setting speed or strength, it quietly ...

A new study shows that in patients with intermediate nonneovascular age-related macular degeneration, levodopa treatment is ...

Wilmington, New Castle, Delaware, April 23, 2024 (GLOBE NEWSWIRE) -- Allied Market Research has recently published a report, titled, “Levodopa Market Size, Share, Competitive Landscape and Trend ...

Please provide your email address to receive an email when new articles are posted on . Apomorphine sublingual film resulted in greater motor improvement and an increase in responders at earlier time ...

The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...

Treatment with Crexont statistically significantly improved “On” time without troublesome dyskinesia compared with carbidopa/levodopa IR. The Food and Drug Administration (FDA) has approved Crexont ® ...

A once-a-week Parkinson’s injection could replace multiple daily pills, thanks to a new slow-release formulation developed by researchers. It promises easier treatment, fewer missed doses, and better ...

Report in the Journal of Parkinson's Disease presents data from one-year trial on long-term safety, efficacy, and quality of life in advanced PD patients using levodopa-carbidopa intestinal gel ...